Renal Cancer Drugs Market

Renal Cancer Drugs Market by therapy (targeted therapy, chemotherapy, and immunotherapy), drug class (anti-angiogenesis, mTOR inhibitors, interleukin, and immune checkpoint inhibitors), indication (renal cell carcinoma, urothelial carcinoma, and others), distribution channel (hospitals, specialty & retail pharmacies and others), and region (North America, Europe, Asia Pacific and Rest of the World (RoW) which includes Latin America and Middle East & Africa) – global forecasts to 2027

Report Code: UC 1416 Mar, 2023, by marketsandmarkets.com

The renal cancer drugs market is projected to reach USD 8 billion by 2027 from USD 6 billion in 2022, at a CAGR of 6% during the forecast period.

To know about the assumptions considered for the study, Request for Free Sample Report

Renal cancer commonly known as kidney cancer originates in the lining of the proximal convoluted tubule of the kidney. Renal cancer is caused by Von Hippel-Lindau (VHL) syndrome, obesity, smoking, high blood pressure, long-term dialysis, and occupational exposure (for example asbestos workers). The symptoms of renal cancer include a lump or mass in the abdomen or side, blood in the urine, weight loss, fever, and lethargy. Several drugs for the treatment of renal cancer are currently available in the market.

The global renal cancer drugs market is likely to show significant growth during the forecast period. This is attributed to the rising incidences of renal cancer, increasing geriatric population, and approval of novel molecules to develop drugs. However, high prices of branded drugs to treat cancer and rising preference for generic drugs are expected to restrain the market for renal cancer drugs market.

The renal cancer drugs market is segmented into five broad categories: by therapy, by drug class, by indication, by distribution channel, and by region. Based on therapy, the market is divided into targeted therapy, chemotherapy, and immunotherapy. The renal cancer drugs class is categorized into anti-angiogenesis, mTOR inhibitors, interleukin, and immune checkpoint inhibitors. Based on indication, the market is segmented into renal cell carcinoma, urothelial carcinoma, and others.

To know about the assumptions considered for the study, download the pdf brochure

Based on distribution channel, the renal cancer drugs market is segmented into hospitals, specialty & retail pharmacies and others. On the basis of region, the renal cancer drugs market is segmented into North America, Europe, Asia Pacific and Rest of the World (RoW) which includes Latin America and Middle East & Africa.

The major players in the renal cancer drugs market are Active Biotech AB (Sweden), Amgen, Inc. (US), Bayer AG (Germany), Cipla Limited (India), F. Hoffmann-La Roche AG (Switzerland), Genentech, Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Onyx Pharmaceuticals, Inc. (US), Pfizer, Inc. (US).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKET COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY
    2.1 RESEARCH DATA
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    2.1.2.1 KEY INDUSTRY INSIGHTS
    2.2 MARKET SIZE ESTIMATION
    2.3 MARKET GROWTH RATE PROJECTIONS
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           5.2.1 DRIVERS
           5.2.2 RESTRAINTS
           5.2.3 OPPORTUNITIES
           5.2.4 CHALLENGES
    5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
    5.4 PRICING ANALYSIS
    5.5 VALUE CHAIN ANALYSIS
    5.6 ECOSYSTEM ANALYSIS
    5.7 PATENT ANALYSIS
    5.8 KEY CONFERENCES AND EVENTS IN 2022-2023
    5.9 REGULATORY ANALYSIS
    5.10 PORTER’S FIVE FORCES ANALYSIS
    5.11 KEY STAKEHOLDER AND BUYING CRITERIA

6 RENAL CANCER DRUGS MARKET, BY THERAPY, 2020-2027 (USD MILLION)
    6.1 INTRODUCTION 
    6.2 TARGETED THERAPY 
    6.3 CHEMOTHERAPY
    6.4 IMMUNOTHERAPY 

7 RENAL CANCER DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    7.1 INTRODUCTION
    7.2 ANTI-ANGIOGENESIS
    7.3 MTOR INHIBITORS
    7.4 INTERLEUKIN
    7.5 IMMUNE CHECKPOINT INHIBITORS

8 RENAL CANCER DRUGS MARKET, BY INDICATION, 2020-2027 (USD MILLION)
    8.1 INTRODUCTION
    8.2 RENAL CELL CARCINOMA
    8.3 UROTHELIAL CARCINOMA
    8.4 OTHERS

8 RENAL CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
    8.1 INTRODUCTION
    8.2 HOSPITAL
    8.3 SPECIALTY & RETAIL PHARMACIES
    8.4 OTHERS

9 RENAL CANCER DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)
    9.1 INTRODUCTION
    9.2 NORTH AMERICA
           9.2.1 US
           9.2.2 CANADA
    9.3 EUROPE
           9.3.1 GERMANY
           9.3.2 FRANCE
           9.3.3 UK
           9.3.4 ITALY
           9.3.5 SPAIN
           9.3.6 ROE
    9.4 ASIA PACIFIC
           9.4.1 JAPAN
           9.4.2 CHINA
           9.4.3 INDIA
           9.4.4 REST OF APAC
    9.5 REST OF THE WORLD (ROW)
           9.5.1 LATIN AMERICA
           9.5.2 MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE
     10.1 OVERVIEW
     10.2 KEY PLAYER STRATEGIES
     10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
     10.4 MARKET SHARE ANALYSIS, 2021
     10.5 COMPANY EVALUATION QUADRANT
     10.6 COMPANY EVALUATION QUADRANT – SME/START-UPS
     10.7 COMPANY GEOGRAPHIC FOOTPRINT
     10.8 COMPETITIVE SCENARIO

11 COMPANY PROFILES
(The details on business overview, financial information, products/services portfolio, recent developments, MarketsandMarkets view will be provided)*
     11.1 ACTIVE BIOTECH AB
     11.2 AMGEN
     11.3 BAYER AG
     11.4 CIPLA LIMITED
     11.5 F. HOFFMANN-LA ROCHE AG
     11.6 GENENTECH INC.
     11.7 GLAXOSMITHKLINE PLC
     11.8 NOVARTIS AG
     11.9 ONYX PHARMACEUTICALS INC.
     11.10 PFIZER INC.

* Details on business overview, financial information, products/services portfolio, recent developments, MarketsandMarkets view might not be captured in case of unlisted companies.

12 APPENDIX
     12.1 INSIGHTS FROM INDUSTRY EXPERTS
     12.2 DISCUSSION GUIDE
     12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
     12.5 AVAILABLE CUSTOMIZATIONS
     12.6 RELATED REPORTS
     12.7 AUTHOR DETAILS


Request for detailed methodology, assumptions & how numbers were triangulated.

Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).
1 6 3 4 8  
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Report Code
UC 1416
Available for Pre-Book
Choose License Type
Prebook Now
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Renal Cancer Drugs Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback